Biomedical subjects
Publications and source records attributed to B Bonavida.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The frequency of lymphoid cells with a membrane receptor for histamine was determined in various lymphoid organs in man using a histamine-rosette assay. Thymus had very low numbers of histamine-receptor cells while lymph node and peripheral blood had increasing percentages. Through a combination of cell separation techniques, we demonstrated that about one third (1/3) of peripheral blood B lymphocytes and macrophages carry histamine receptors. Immature B cells or null cells (E-rosette and membrane-immunoglobulin-negative) do not have this receptor. Only 10% of peripheral blood T lymphocytes formed histamine rosettes. That these histamine receptor T lymphocytes are a subpopulation representing the differentiated suppressor/cytotoxic T cells is suggested by evidence showing complete removal of histamine receptor T lymphocytes on nylon wool adherence columns. Thus, the histamine receptor is expressed on differentiated B and T lymphocytes and may serve as a marker for developed suppressor/cytotoxic T cells in man.
Three reticulum cell sarcoma lines (LA1, LA6, and LA8) have been established from SJL/J spontaneous "Hodgkin's-like" reticulum cell sarcoma. All cultures are lymphoid with blast-like morphology by light and electron microscopy and produce the type B neoplasm (Dunn classification) when injected into young SJL/J mice. Identification of these tumors as lymphocytic and monocytic was investigated by surface markers, histochemical staining, and phagocytic function. LA6 and LA8 bear receptors for the Fc portion of immunoglobulin complement receptors; Thy 1.2 antigens and surface immunoglobulin were not detected on any of the three lines. No lines were able to synthesize immunoglobulin or phagocytose Degalon beads. Histochemical staining was presumptive of lymphocytes or lymphoblasts with slight differences between the lines. Although a T- or B-cell classification cannot definitively be made for these tumors lines because of their lack of specific markers, the results are consistent with an immature B-cell origin for the SJL/J reticulum cell sarcoma.
Explore the source record for details and available documents.
Circulating soluble tumor antigens were detected in the serum of tumor-bearing rats. Sublethally irradiated W/Fu rats inoculated with syngeneic C58(NT)D Gross virus-induced lymphoma served as the source of tumor antigens. Soluble antigens were assessed by specific inhibition of the complement-mediated cytotoxicity of isogenic W/Fu anti-C58(NT)D antibodies against 51Cr tumor target cells. With a s.c. inoculum of 5 X 10(7) tumor cells, circulating tumor antigens were first detected at Day 8, and a maximum concentration was reached by Day 13 to 14, which coincided with the peak of tumor growth and was followed by the sudden death of the animals. Pooled serum from tumor-bearing rats was fractioned on Sephadex G-150 and resulted in one peak that contained all of the antigenic activity. The molecular weight of this fraction was estimated to be 50,000 to 60,000 daltons. Presensitization of normal rats with soluble tumor antigens resulted in a specific acceleration of tumor growth and delay in tumor rejection. Specificity was shown by lack of C58(NT)D tumor enhancement in rats presensitized with serum containing tumor antigens from a syngeneic but antigenically unrelated WR-6 lymphoma. The biological significance of circulating soluble tumor antigen mediating specific immunosuppression against an immunogenic tumor is discussed.
Explore the source record for details and available documents.
NZB and NZB/W mice have reduced anti-sheep red cell (SRC) and 2,4,6-trinitrophenyl-plaque-froming cell (TNP-PFC) responses with age after injection of either the thymus-dependent antigen TNP-SRC or the thymus-independent antigen TNP-mouse red cells (MRC). However, the thymus-dependent response diminished much faster than the thymus-independent response. As a consequence, young New Zealand mice have a higher anti-TNP response after injection of TNP-SRC than after injection of TNP-MRC, while old New Zealand mice have a higher anti-TNP response after injection of TNP-MRC than after injection of TNP-SRC. The PFC avidity of NZB/W mice injected with TNP-SRC diminished with age, while the PFC avidity of mice injected with TNP-MRC did not change with agrc or TNP-SRC. Old NZB/W mice had few spontaneous anti-MRC-PFC. The number of anti-MRC PFC in old mice was increased 4 to 10 times after injection with either TNP-SRC or TNP-MRC. It is suggested that surveillance mechanisms are responsible for suppressing the autoimmune response to modified self-antigens. The unregulated immune system of NZB and NZB/W mice appears to be an expression of impairment of such a hypothetical surveillance mechanism.
H-2d mice treated before skin grafting with either soluble alloantigen prepared from H-2b cells or with serum obtained from similarly sensitized mice showed a significantly prolonged survival of H-2b skin allografts. This in vivo enhancement was paralleled by a depression of cell-mediated cytotoxicity to [51Cr]H-2b target cells in vitro. Such in vitro and in vivo effects were abrogated when mice were repeatedly injected with soluble alloantigen before and after skin grafting, demonstrating that enhancing antibody present could be neutralized by this mode of antigen administration. The data suggest that serum factors present in mice pretreated with soluble alloantigen lead to specific blocking at the induction phase of the cell-mediated immune response and result in skin graft enhancement.
Murine lymphoid cells sensitized against allografts express two types of cytotoxicity measured in vitro in short-term assays of 2 to 3 hr by 51Cr release. One type of cytotoxicity is specific against target cells carrying the sensitizing alloantigens, and the other type is nonspecific against both syngeneic and unrelated target cells and requires the presence of phytohemagglutinin (PHA) or concanavalin A (ConA). Several lines of evidence are presented which demonstrate that both cytotoxic systems are mediated by the same clone of alloimmune effector T lymphocytes and that the lectin-induced cytotoxicity is not attributable to mitogenic polyclonal activation of effector cells. Studies with ConA inhibitor alpha-methyl-D-mannoside suggest a mechanism of interaction that requires the lectin to be present during the reaction. Experiments with other reagents, however, that bring about physical contact of the cells but not lysis, indicate that cytolysis can occur only through specific lectin receptors on the cells. The significance of this lectin-induced cytotoxicity is discussed.
The ability of trinitrophenylated tumor cells to stimulate syngeneic antitumor response has been tested in 3 different tumor-host systems: A. Trinitrophenylated and inactivated Moloney induced YAC tumor cells (YAC-TNP) were able to induce the production of cytotoxic antibodies in low responding A/J mice, while inactivated YAC tumor cells (YAC-In) failed to induce such a response. Furthermore, A mice which were injected with YAC-TNP rejected 103 viable YAC tumor cells at a higher frequency than those injected with YAC-In. B. Trinitrophenylated and inactivated Gross virus induced G-35 tumor cells or Monoloney induced LSTRA cells (both syngeneic in BALB/c mice) were as immunogenic as nonmodified inactivated tumor cells. About 50% of the immunized mice survived indefinitely after injection of 103 viable tumors. Fruthermore, spleen cells from mice primed with either modified or nonomodified G-35 cells responded in vitro to G-35 in a mixed leukocyte tumor interaction and generated specific cell-mediated cytotoxic activity to 51Cr-G-35 syngeneic tumors. However, the donors of the primed cells did not produce detectable cytotoxic antibodies to G-35. C. In vitro sensitization of C57B1 spleen cells by trinitrophenylated Mitomycin C treated syngeneic EL-4 generated a stronger cytotoxic response to EL-4 cells than obtained by sensitization with Mitomycin C treated EL-4 cells alone, The superiority of the sensitizing capacity of trinitrophenylated EL-4 was readily demonstrated in conditions which were suboptimal for nonmodified Mitomycin C treated tumor. Both theoretical and practical implications of these results are discussed.
W/Fu rats inoculated s.c. with less than or equal to 5 x 10(7) syngeneic (C58NT)D (Gross virus-positive) lymphoma tumor cells normally develop a palpable tumor which reaches its maximum size (12 to 14 mm) at 6 to 8 days and is subsequently rejected by 10 to 12 days. However, rats previously sensitized with soluble tumor antigens from (C58NT)D cells prior to (C58NT)D tumor inoculation demonstrate a significant enhancement of tumor growth (the tumor reaches up to 26 mm and is rejected by 16 to 18 days). This enhancement persisted in antigen-treated rats that continued to receive soluble antigen after tumor inoculation. The in vivo enhancement coincided with a significant in vitro depression of cell-mediated cytotoxicity [assessed with 51Cr-labeled (C58NT)D target cells and peripheral blood leukocytes]. The observed tumor enhancement was specific, inasmuch as presensitization to either soluble tumor antigens from WR6 (Gross virus-negative) tumor, syngeneic to W/Fu rats, or to soluble antigen from W/Fu spleen cells had no enhancing effect on (C58NT)D tumor growth. Interestingly, sensitization to soluble tumor antigen alone did not elicit detectable cell-mediated immunity, cytotoxic antibody, or serum-blocking activity to the (C58NT)D tumor. We conclude that sensitization to soluble tumor antigens specifically impairs the immune apparatus normally acting in tumor rejection. This impairment appears to act primarily at the induction phase of the immune response.
Spontaneous reticulum cell sarcoma in SJL/J mice has been proposed as an animal tumor model for Hodgkin's lymphoma. The relationship of tumor progression and immune function is not clear, however, and has prompted a systematic evaluation of SJL/J immune competence. It was found that the ability to generate cell-mediated immunity and antibody response to allografts was not impaired in 2- to 12-month-old mice, regardless of their tumor status. All animals were capable of generating in vivo cytotoxic effector T-cells and both IgG and IgM classes of cytotoxic antibody to a tumor allograft. In addition to being able to respond, older mice showed an unexpected hyperresponsiveness to alloantigens, which suggested that escape from feedback control might be a characteristic of SJL/J mice. Loss of immune regulation was further indicated by the failure to induce tolerance to human gamma-globulin in mice 4 months and older, while 3-week-old SJL/J mice could be rendered unresponsive. Coincident with this apparent loss of regulation, circulating antibodies to synthetic double-stranded RNA, polyinosinis - polycytidylic acid, were first detected in unimmunized mice at 4 months of age, and titers remained elevated regardless of tumor status. It is suggested that tumor development as well as autoimmunity may result from an effective amplification of the immune response.
Mice of 1.5, 9, 22, and 31 to 32 months of age were injected with the thymus-dependent antigen, TNP-SRC, or the thymus-independent antigen, TNP-SRC, TNP-MRC. The anti-SRC and TNP immune responses to TNP-SRC were markedly reduced in older mice, whereas the anti-TNP response to the TNP-MRC showed no substantial decline. Young mice produced higher anti-TNP plaque-forming cell responses after injection of TNP-SRC than after TNP-MRC, whereas in older mice the reverse obtained. Old mice but not young mice displayed a high anti-SRC cross-reactive response after injection of TNP-MRC. The avidity of anti-TNP antibody of young mice immunized with TNP-SRC was higher than that following immunization with TNP-MRC, whereas the avidities of anti-TNP antibodies from old mice injected with these two reagents were the same. Those individual mice which showed a poorly regulated immune response also displayed an autologous anti-MRC plaque-forming cell response after injection of either TNP-SRC or TNP-MRC. It is suggested that mechanisms mediated by suppressor T cells may be responsible for regulating the autoimmune response to modified self antigens, and that these are severely impaired in age individuals.
Two non-overlapping populations of alloimmune cytotoxic T cells with specificity for tumor-associated antigens (TAA) and for histocompatibility antigens (H-2) were characterized by two independent methods. The heterogeneity of cytotoxic cells was demonstrated in spleen cells derived from BALB/c (H-2d) mice sensitized to EL-4 (H-2b) tumor and from C57BL/6 (H-2b) mice sensitized to G-35 (H-2d) tumor cells. Adsorption of immune lymphocytes on monolayers prepared with cells bearing the sensitizing H-2 antigens abrogated the in vitro cell-mediated cytotoxicity (CMC) directed against 51Cr-labeled normal target cells (spleen cells or ConA-activated spleen blasts), whereas significant cytolytic activity to the corresponding 51Cr-tumor cells was still retained. Likewise, in competitive inhibition assays, CMC to 51 Cr-tumor target cells was only partially inhibited by unlabeled normal cells, whereas CMC to 51Cr-normal target cells was completely abrogated. These results suggested that alloimmune cytotoxic lymphocytes are heterogeneous and can be subdivided into two independent populations of restricted specificity. Several experiments suggested that the effector cell population directed against TAA can no longer elicit a graft-vs-host (GVH) reaction in vivo. This was demonstrated by adoptive transfer into lethally-irradiated allogeneic recipients of cytotoxic or primed spleen cells fractionated on host target cell monolayers. Furthermore, these results demonstrated that both effector cells and memory cells possess high affinity binding receptors to corresponding H-2 antigens. The potential use of fractionated immune lymphocytes sensitized to tumor allografts in adoptive immunotherapy is discussed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.